Form 4: Anteris Technologies CEO Wayne Paterson Reports Stock and Option Transactions Following IPO

Anteris Technologies CEO Wayne Paterson reports the acquisition of common stock and various stock options following the company's U.S. initial public offering and reorganization.

Summary

• Wayne Paterson, CEO of Anteris Technologies, filed a Form 4 detailing transactions related to the company's recent U.S. initial public offering (IPO) and reorganization.
• Paterson received 20,334 shares of common stock in exchange for an equivalent number of ordinary shares of Anteris Technologies Ltd (ATL) as part of the reorganization.
• He also acquired multiple stock options with varying exercise prices and vesting schedules, all assumed from legacy awards originally issued by ATL.
• The options have exercise prices ranging from $3.76 to $23.56, translated from AUD to USD using a rate of A$1.00 to $0.64.
• The options vest over different periods, some beginning as early as 2018 and others as late as 2025, subject to continued service.
• The closing price of Anteris Technologies' common stock on the effective date of the IPO was $5.50 per share.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of executive stock and option transactions following an IPO. It is neither particularly positive nor negative, but indicates alignment of management interests with shareholders.

Positives

• The CEO's acquisition of shares and options aligns his interests with the company's success.
• The vesting schedules of the options provide an incentive for continued service and performance.
• The reorganization and IPO have resulted in the CEO holding a significant number of shares and options in the new entity.

Industry Context

This filing is a standard disclosure following a company's IPO and reorganization, showing the CEO's initial holdings in the newly formed entity. It is common for executives to receive stock and options as part of their compensation packages.

Comparison to Industry Standards

• The granting of stock options to executives is a common practice in the biotechnology and medical device industries, similar to companies like Medtronic, Boston Scientific, and Abbott.
• The vesting schedules of these options are also typical, designed to incentivize long-term performance and retention, which is consistent with industry norms.
• The conversion of legacy options from the predecessor company (ATL) to the new entity is a standard procedure during a reorganization, similar to what occurs in mergers and acquisitions.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding the CEO's holdings in the company.
• The vesting schedules of the options align the CEO's interests with the long-term success of the company, which is beneficial for shareholders.

Key Dates

Keywords

Anteris Technologies, Wayne Paterson, Form 4, Stock Options, IPO, Reorganization, Beneficial Ownership, Executive Compensation, Share Acquisition